Unleashing the power of Attobody® technology to develop novel therapeutics
ATTOBODIES are small format biparatopic biologics that solve the size and flexibility limitation of traditional treatments. By utilizing a proprietary spatial positioning technology, ATTOBODIES unlock a new dimension of target engagement.
The biparatopic binding mode of ATTOBODIES translates to picomolar affinity with glue-like off-rates, exquisite specificity, and accelerated target internalization. Their small format and modularity offer fast tissue penetration, ease of engineering into multi-specifics, and tunable half-life from hours to weeks. Collectively, these properties of ATTOBODIES expand the addressable target and epitope universe across disease areas and can offer stronger efficacy, faster speed to response, and an improved safety profile compared to traditional approaches.
Unleashing the power of Attobody® technology to develop novel therapeutics
ATTOBODIES are small format biparatopic biologics that solve the size and flexibility limitation of traditional treatments. By utilizing a proprietary spatial positioning technology, ATTOBODIES unlock a new dimension of target engagement. The biparatopic binding mode of ATTOBODIES translates to picomolar affinity with glue-like off-rates, exquisite specificity, and accelerated target internalization. Their small format and modularity offer fast tissue penetration, ease of engineering into multi-specifics, and tunable half-life from hours to weeks. Collectively, these properties of ATTOBODIES expand the addressable target and epitope universe across disease areas and can offer stronger efficacy, faster speed to response, and an improved safety profile compared to traditional approaches.
ATTOBODIES: positioning for cures
ATTOBODIES are composed of two paratopes connected through proprietary spatial positioning technology. This technology orients the paratopes in an optimal configuration to drive desired target engagement.
Currently, our ATTOBODIES utilize VHHs as their binder arms. The VHH format is a well-understood framework that is clinically and commercially validated. In the future, we envision bringing additional binder options to our platform to further broaden our potential at targeting diseases that remain unaddressed by current treatments.
ATTOBODIES are a flexible modality that can be used in their native form, as well as easily built out as bi- and multimers, fused to Fc-domains to modulate effector functions or extending half-life. or conjugated to cytotoxic, immunomodulatory or radiotherapeutic payloads.
The ATTOBODY advantage
Enhanced efficacy
Biparatopic binding offers strong binding affinity with glue-like off-rate. This can enable deeper efficacy through extended target occupancy.
Exquisite specificity
By interacting with two epitopes on target molecules, ATTOBODIES achieve high specificity of target recognition. This allows them to differentiate between closely related target molecules such as GPCRs, ion channels or tumor-specific variants that cannot be easily addressed by traditional approaches.
Improved internalization for more effective tumor eradication
The biparatopic binding mode of ATTOBODIES drives enhanced internalization when compared to IgGs or nanobodies. This makes ATTOBODIES a modality of choice for payload delivery medicines such as drug conjugates or radioconjugates.
Improved tissue penetration for faster responses
The small format of ATTOBODIES can offer faster tissue penetration and target modulation at disease site translating to faster, deeper responses.
Optimized PK/PD for efficacious, tolerable treatments
Combined with their enhanced target affinity, the small format of ATTOBODIES improves their therapeutic index when used as a payload delivery modality for oncology treatments. Tumor-targeted Atto-conjugate penetrates tumor tissue quickly, binds to desired protein target and remains bound longer due to glue-like off-rate/internalizes quickly. Unbound, systemic fraction is quickly washed out of the system, reducing harmful side effects.
Flexible formats
ATTOBODIES are highly modular. They can be used in their native format, combined into bi- and multi-specifics, fused to a variety of half-life extension fragments that can offer up to every two-three months dosing, as well as conjugated to payloads.
Enhanced efficacy
Biparatopic binding offers strong binding affinity with glue-like off-rate. This can enable deeper efficacy through extended target occupancy.
Exquisite specificity
By interacting with two epitopes on target molecules, ATTOBODIES achieve high specificity of target recognition. This allows them to differentiate between closely related target molecules such as GPCRs, ion channels or tumor-specific variants that cannot be easily addressed by traditional approaches.
Improved internalization for more effective tumor eradication
The biparatopic binding mode of ATTOBODIES drives enhanced internalization when compared to IgGs or nanobodies. This makes ATTOBODIES a modality of choice for payload delivery medicines such as drug conjugates or radioconjugates.
Improved tissue penetration for faster responses
The small format of ATTOBODIES can offer faster tissue penetration and target modulation at disease site translating to faster, deeper responses.
Optimized PK/PD for efficacious, tolerable treatments
Combined with their enhanced target affinity, the small format of ATTOBODIES improves their therapeutic index when used as a payload delivery modality for oncology treatments. Tumor-targeted Atto-conjugate penetrates tumor tissue quickly, binds to desired protein target and remains bound longer due to glue-like off-rate/internalizes quickly. Unbound, systemic fraction is quickly washed out of the system, reducing harmful side effects.
Flexible formats
ATTOBODIES are highly modular. They can be used in their native format, combined into bi- and multi-specifics, fused to a variety of half-life extension fragments that can offer up to every two-three months dosing, as well as conjugated to payloads.
ATTOBODIES: the binder of choice across multiple modalities
Due to their innate small size and flexibility, modularity of formats, and attractive biophysical properties, ATTOBODIES can be binders of choice across modalities. The spatial positioning aspect of our technology can improve the efficacy and/or tolerability of agonists, antagonists, cell therapies, drug conjugates, and beyond. We are open to collaborations exploring the potential of our ATTOBODIES to enrich and improve our partners’ development pipelines and discovery efforts.
